#Cross-chain infrastructure SYNTHR raises $10 million.#
Hot Topic Overview
Overview
SYNTHR, a cross-chain infrastructure, has announced the completion of its Series A funding round, raising $10 million from investors including Kronos, NGC Ventures, and Morningstar Ventures. In addition, the project has received 11 grants from Oasis Network, Sui, Sei, and others. SYNTHR is a cross-chain asset protocol built on Layer Zero, and also a synthetic asset protocol, allowing users to mint and trade on-chain derivatives.
Ace Hot Topic Analysis
Analysis
Cross-chain infrastructure SYNTHR recently announced the completion of its Series 5 funding round, raising a total of $10 million. The round was led by Kronos, NGC Ventures, Morningstar Ventures, and others. In addition, the project received 11 grants from Oasis Network, Sui, Sei, and others. SYNTHR is a cross-chain asset protocol designed on Layer Zero, and also a synthetic asset protocol that allows users to mint and trade on-chain derivatives. The funds will be used to further develop the SYNTHR protocol and expand its application in the cross-chain field. The success of SYNTHR's financing demonstrates the market's recognition of cross-chain infrastructure and synthetic asset protocols, and also reflects investors' optimism about the future development of cross-chain technology.
Public Sentiment · Discussion Word Cloud
Public Sentiment
Discussion Word Cloud
Classic Views
SYNTHR is a cross-chain asset protocol designed by Layer Zero that enables users to mint and trade on-chain derivatives.
SYNTHR has completed 5 rounds of funding, raising a total of $10 million, attracting investments from well-known institutions such as Kronos, NGC Ventures, and Morningstar Ventures.
SYNTHR has also received 11 funding grants from Oasis Network, Sui, Sei, and others, demonstrating its potential for growth in the cross-chain space.
SYNTHR's cross-chain infrastructure provides users with a more convenient cross-chain asset trading experience and drives the development of synthetic asset protocols.